RBC Capital lowered the firm’s price target on CorMedix (CRMD) to $13 from $22 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- P/E Steals: 3 Overlooked Stocks Ready to Surge Over 100% in 2026
- Cormedix: Near-Term Reimbursement Headwinds but Compelling Long-Term Upside Supports Buy Rating and $18 Target
- Cormedix: Market Overreaction to 2026 Guidance Creates Undervalued Buy Opportunity
- CorMedix price target lowered to $16 from $20 at Truist
- Midday Fly By: Defense stocks surge on Trump budget request